CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Hayashi Kasei, a leading siRNA supplier in Japan and Korea, announced today that Alnylam has granted Hayashi Kasei a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
